DEEP DIVE into (LDN) Low Dose Naltrexone with Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPh

Low Dose Naltrexone (LDN) Clearly from the adjectives it’s a “non standard” dosage from what naltrexone was originally intended. But why?

LDN is a method (with EXTENSIVE data) of finding benefits to healing from certain issues that have often left people hopeless.

Weight management, nerve damage, palsy, autoimmune thyroid disorders, cancer, chronic fatigue syndrome, chronic pain,Crohn’s diease, fibromyalgia, PTSD, multiple sclerosis, myalgic encephalomyelitis.

The GCP welcomes three experts and Clinical Compounding Pharmacists to share with you their knowledge and experience in helping people find comfort and happiness again in their lives! Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPh join Ken & Eric to discuss the hype and evidence around LDN.

REFERENCES

https://a4pc.org/

https://www.pccarx.com/Resources/FindACompounder

https://www.achc.org/compounding-pharmacy/

https://ldnresearchtrust.org/

https://ldnresearchtrust.org/2024_LDN_Guides

https://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf

current dosing recommendations

https://www.jpsmjournal.com/article/S0885-3924%2803%2900139-8/fulltext

Ultra low dose early info

Purdue had Oxycontin and the combination was used clinically and was pursued, then Oxytrex was the trade name-2005 phase 3 trials, by a company Pain Therapeutics-but did not launch or fully launch

TROXYCA® ER is a Pfizer product in 2016 (higher doses)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207621s004lbl.pdf